Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fludarabine + cytarabine + liposomal daunorubicin (Region Västra Götaland)
- Development stage
- Unknown
- Lead developer
- Västra Götalandsregionen
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
FLADx is a multi-agent combination chemotherapy regimen primarily utilized in the treatment of pediatric acute myeloid leukemia (AML). It consists of three active cytotoxic agents: fludarabine (a purine nucleoside antimetabolite), high-dose cytarabine (a pyrimidine nucleoside antimetabolite), and DaunoXome (a liposomal formulation of the anthracycline daunorubicin). The regimen is typically employed as an intensified induction therapy. In the NOPHO-DBH AML 2012 Phase III trial, FLADx was evaluated as a second induction course, compared against the ADxE regimen, to improve outcomes in pediatric patients. The treatment protocol often incorporates minimal residual disease (MRD) monitoring to guide risk stratification and subsequent therapeutic decisions, such as the allocation to allogeneic stem cell transplantation for high-risk patients.
- Other names
- FLADxFLA-Dx
02
Targets
DNALigA (DNA ligase (NAD(+)-dependent))DNA polymerase familyDNA-directed primase/polymerase protein (PrimPol)TOP2A (DNA topoisomerase II)Pol II (RNA polymerase II elongation factors)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on fludarabine + cytarabine + liposomal daunorubicin (Region Västra Götaland).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fludarabine + cytarabine + liposomal daunorubicin (Region Västra Götaland).